Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03270969 · ClinicalTrials.gov registry record · Phase 1
A Pharmacokinetic Evaluation of Tenofovir/Emtricitabine as HIV Pre-Exposure Prophylaxis in Transgender Women
A Phase 1 study, sponsored by University of Nebraska.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT03270969 is a Phase 1 study that has completed, run by University of Nebraska. The registered enrollment target is 15 participants.
The verdict
NCT03270969, a Phase 1 study, has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
Human immunodeficiency virus (HIV) persists worldwide as an immense health burden among vulnerable populations. HIV pre-exposure prophylaxis (PrEP) has offered the promise of limiting the global burden of HIV. The objective of this proposal is to conduct a pharmacokinetic (PK) study in transgender women to describe the pharmacokinetics of tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) as PrEP within this population.
Interventions
- DRUG Tenofovir Disoproxil Fumarate/Emtricitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2018-01-05 |
| Est. Completion | 2018-09-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03270969
The ClinicalTrials.gov registry entry for NCT03270969 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tenofovir Disoproxil Fumarate/Emtricitabine is the first listed.
NCT03270969 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03270969 about?
NCT03270969 is a clinical study titled "A Pharmacokinetic Evaluation of Tenofovir/Emtricitabine as HIV Pre-Exposure Prophylaxis in Transgender Women". Human immunodeficiency virus (HIV) persists worldwide as an immense health burden among vulnerable populations. HIV pre-exposure prophylaxis (PrEP) has offered the promise of limiting the global burden of HIV. The objective of this proposal is to conduct a pharmacokinetic (PK) study in transgender w...
What is the current status of trial NCT03270969?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2018-01-05. Estimated completion is 2018-09-10.
What interventions are being tested in trial NCT03270969?
The interventions under investigation include: Tenofovir Disoproxil Fumarate/Emtricitabine (DRUG).
Who is sponsoring clinical trial NCT03270969?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.